Free-pricing holiday for new drugs in Germany a potential target
This article was originally published in SRA
Executive Summary
Drug companies in Germany could see lower prices for their new products take effect sooner and potential delays to launch if German policymakers do away with the 12-month grace period of free pricing for new drugs before the outcome of early benefit assessments and pricing talks kick in. The warning comes from Wolfgang Kaesbach, a former head of the pharmaceutical department of the GKV, the national association of statutory health insurers.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.